Drug Profile
Virus inactivated dried plasma - Entegrion
Alternative Names: ResusixLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Entegrion
- Developer Entegrion; Kedrion
- Class Anti-infectives; Anti-inflammatories; Anticoagulants; Antihaemorrhagics; Blood products and substitutes
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Blood coagulation disorders; Haemorrhage
Most Recent Events
- 07 Dec 2022 No development reported - Phase-II for Blood coagulation disorders in USA (IV)
- 08 Jan 2021 Entegrion terminates a phase-II clinical trials in Blood coagulation disorders in USA (IV) because of convenience of Government funding sponsor (NCT03700723)
- 28 Oct 2020 No recent reports of development identified for phase-I development in Haemorrhage in USA (IV, Infusion)